Revenue
2021
2022
2023
2024
2025
2026
Medincell (MEDCL)
Price€22.80Cached quote
Net income
2021
2022
2023
2024
2025
2026
Free cash flow
2021
2022
2023
2024
2025
2026
Total cash / debt
CashTotal debt
2021
2022
2023
2024
2025
2026
Financial statements
| 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue | €24.3M | €27.7M | €11.9M | €13.7M | €8.3M | €11.8M |
| Gross profit | €24.3M | €27.7M | €11.9M | €13.7M | €8.3M | €11.8M |
| Gross margin | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| Research & development | €26.5M | €24.3M | €21.1M | €27.9M | €23.6M | €19.5M |
| Operating expenses | €45.0M | €38.5M | €32.9M | €37.7M | €32.2M | €27.4M |
| Operating income | −€20.8M | −€10.8M | −€21.0M | −€24.0M | −€23.8M | −€15.6M |
| Operating margin | −85.60% | −39.10% | −175.61% | −176.10% | −285.61% | −132.28% |
| EBITDA | −€19.0M | −€8.8M | −€19.3M | −€22.4M | −€22.3M | −€14.2M |
| EBITDA margin | −78.09% | −31.92% | −161.22% | −163.90% | −267.43% | −120.91% |
| Net income | −€31.3M | −€18.4M | −€25.0M | −€32.0M | −€24.8M | −€19.0M |
| Net profit margin | −128.88% | −66.50% | −209.61% | −234.42% | −297.51% | −161.24% |
| Basic EPSper basic share | -€0.94 | -€0.62 | -€0.88 | -€1.27 | -€1.00 | -€0.86 |
| Diluted EPSper diluted share | -€0.94 | -€0.62 | -€0.88 | -€1.27 | -€1.00 | -€0.86 |